Production of recombinant allergens in plants

F. Ferreira, G. Schmidt, G. Gadermaier, Anneli Ritala, G. Obermeyer

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

Abstract

The routine diagnostic set-up for atopic allergies includes detailed documentation of the clinical history, provocation tests in skin or other target organs, and serology (laboratory tests for total and allergen-specific IgE antibodies). Since decades, skin tests and other provocation tests, as well as allergen immunotherapy are performed with extracts from natural sources. Presently, these extracts are standardized for their content of certain major allergens, a prerequisite for the production of consistent preparations. However, products prepared from natural sources are very heterogeneous and contain many allergenic and non-allergenic proteins, and other substances. Thus, the replacement of extracts by selected recombinant allergens is an emerging strategy for improving allergy diagnosis and immunotherapy. In this respect, recombinant production based on plant systems offers a number of advantages such as appropriate post-translational modifications and enhanced safety due to absence of animal or human pathogens. So far, several approaches to express allergens using plant systems have been published. Immunologically active Der p 2, a major house dust mite (HDM) allergen, has been expressed in BY-2 tobacco suspension cell cultures. Mal d 2, a thaumatin-like allergenic protein from apple, and Bet v 1, the major birch pollen allergen, both have been overexpressed in Nicotiana benthamiana using a tobacco mosaic virus (TMV) vector. The major mugwort pollen allergen Art v 1 has been expressed in both TMV and Agrobacterium-transformed tobacco plants. Other approaches have explored the possibility of using seeds of cereal crops as vehicles for production of recombinant allergens and as direct delivery system without the need of allergen extraction and purification. Prototypes of such edible vaccines have been produced for a major HDM allergen Der f 1 in Lotus japonicus, and for T cell epitopes of Japanese cedar pollen allergens in rice seeds.
Original languageEnglish
Title of host publicationPlants for Human Health in the Post-Genome Era
Subtitle of host publicationPSE Congress
Place of PublicationEspoo
PublisherVTT Technical Research Centre of Finland
Pages37-37
ISBN (Electronic)978-951-38-6322-7
ISBN (Print)978-951-38-6321-0
Publication statusPublished - 2007
EventPSE Congress: Plants for Human Health in the Post-Genome Era - Helsinki, Finland
Duration: 26 Aug 200729 Aug 2007

Publication series

NameVTT Symposium
PublisherVTT
Number249
ISSN (Print)0357-9387

Conference

ConferencePSE Congress: Plants for Human Health in the Post-Genome Era
CountryFinland
CityHelsinki
Period26/08/0729/08/07

Fingerprint

allergens
dust mites
Tobacco mosaic virus
skin tests
immunotherapy
pollen
hypersensitivity
extracts
tobacco
edible vaccines
Artemisia vulgaris
Lotus corniculatus var. japonicus
Cryptomeria japonica
Nicotiana benthamiana
post-translational modification
arts
grain crops
seeds
Agrobacterium
Betula

Cite this

Ferreira, F., Schmidt, G., Gadermaier, G., Ritala, A., & Obermeyer, G. (2007). Production of recombinant allergens in plants. In Plants for Human Health in the Post-Genome Era: PSE Congress (pp. 37-37). [O22] Espoo: VTT Technical Research Centre of Finland. VTT Symposium, No. 249
Ferreira, F. ; Schmidt, G. ; Gadermaier, G. ; Ritala, Anneli ; Obermeyer, G. / Production of recombinant allergens in plants. Plants for Human Health in the Post-Genome Era: PSE Congress. Espoo : VTT Technical Research Centre of Finland, 2007. pp. 37-37 (VTT Symposium; No. 249).
@inbook{b563462c1a014012a171fd58fbb41a60,
title = "Production of recombinant allergens in plants",
abstract = "The routine diagnostic set-up for atopic allergies includes detailed documentation of the clinical history, provocation tests in skin or other target organs, and serology (laboratory tests for total and allergen-specific IgE antibodies). Since decades, skin tests and other provocation tests, as well as allergen immunotherapy are performed with extracts from natural sources. Presently, these extracts are standardized for their content of certain major allergens, a prerequisite for the production of consistent preparations. However, products prepared from natural sources are very heterogeneous and contain many allergenic and non-allergenic proteins, and other substances. Thus, the replacement of extracts by selected recombinant allergens is an emerging strategy for improving allergy diagnosis and immunotherapy. In this respect, recombinant production based on plant systems offers a number of advantages such as appropriate post-translational modifications and enhanced safety due to absence of animal or human pathogens. So far, several approaches to express allergens using plant systems have been published. Immunologically active Der p 2, a major house dust mite (HDM) allergen, has been expressed in BY-2 tobacco suspension cell cultures. Mal d 2, a thaumatin-like allergenic protein from apple, and Bet v 1, the major birch pollen allergen, both have been overexpressed in Nicotiana benthamiana using a tobacco mosaic virus (TMV) vector. The major mugwort pollen allergen Art v 1 has been expressed in both TMV and Agrobacterium-transformed tobacco plants. Other approaches have explored the possibility of using seeds of cereal crops as vehicles for production of recombinant allergens and as direct delivery system without the need of allergen extraction and purification. Prototypes of such edible vaccines have been produced for a major HDM allergen Der f 1 in Lotus japonicus, and for T cell epitopes of Japanese cedar pollen allergens in rice seeds.",
author = "F. Ferreira and G. Schmidt and G. Gadermaier and Anneli Ritala and G. Obermeyer",
year = "2007",
language = "English",
isbn = "978-951-38-6321-0",
series = "VTT Symposium",
publisher = "VTT Technical Research Centre of Finland",
number = "249",
pages = "37--37",
booktitle = "Plants for Human Health in the Post-Genome Era",
address = "Finland",

}

Ferreira, F, Schmidt, G, Gadermaier, G, Ritala, A & Obermeyer, G 2007, Production of recombinant allergens in plants. in Plants for Human Health in the Post-Genome Era: PSE Congress., O22, VTT Technical Research Centre of Finland, Espoo, VTT Symposium, no. 249, pp. 37-37, PSE Congress: Plants for Human Health in the Post-Genome Era, Helsinki, Finland, 26/08/07.

Production of recombinant allergens in plants. / Ferreira, F.; Schmidt, G.; Gadermaier, G.; Ritala, Anneli; Obermeyer, G.

Plants for Human Health in the Post-Genome Era: PSE Congress. Espoo : VTT Technical Research Centre of Finland, 2007. p. 37-37 O22 (VTT Symposium; No. 249).

Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

TY - CHAP

T1 - Production of recombinant allergens in plants

AU - Ferreira, F.

AU - Schmidt, G.

AU - Gadermaier, G.

AU - Ritala, Anneli

AU - Obermeyer, G.

PY - 2007

Y1 - 2007

N2 - The routine diagnostic set-up for atopic allergies includes detailed documentation of the clinical history, provocation tests in skin or other target organs, and serology (laboratory tests for total and allergen-specific IgE antibodies). Since decades, skin tests and other provocation tests, as well as allergen immunotherapy are performed with extracts from natural sources. Presently, these extracts are standardized for their content of certain major allergens, a prerequisite for the production of consistent preparations. However, products prepared from natural sources are very heterogeneous and contain many allergenic and non-allergenic proteins, and other substances. Thus, the replacement of extracts by selected recombinant allergens is an emerging strategy for improving allergy diagnosis and immunotherapy. In this respect, recombinant production based on plant systems offers a number of advantages such as appropriate post-translational modifications and enhanced safety due to absence of animal or human pathogens. So far, several approaches to express allergens using plant systems have been published. Immunologically active Der p 2, a major house dust mite (HDM) allergen, has been expressed in BY-2 tobacco suspension cell cultures. Mal d 2, a thaumatin-like allergenic protein from apple, and Bet v 1, the major birch pollen allergen, both have been overexpressed in Nicotiana benthamiana using a tobacco mosaic virus (TMV) vector. The major mugwort pollen allergen Art v 1 has been expressed in both TMV and Agrobacterium-transformed tobacco plants. Other approaches have explored the possibility of using seeds of cereal crops as vehicles for production of recombinant allergens and as direct delivery system without the need of allergen extraction and purification. Prototypes of such edible vaccines have been produced for a major HDM allergen Der f 1 in Lotus japonicus, and for T cell epitopes of Japanese cedar pollen allergens in rice seeds.

AB - The routine diagnostic set-up for atopic allergies includes detailed documentation of the clinical history, provocation tests in skin or other target organs, and serology (laboratory tests for total and allergen-specific IgE antibodies). Since decades, skin tests and other provocation tests, as well as allergen immunotherapy are performed with extracts from natural sources. Presently, these extracts are standardized for their content of certain major allergens, a prerequisite for the production of consistent preparations. However, products prepared from natural sources are very heterogeneous and contain many allergenic and non-allergenic proteins, and other substances. Thus, the replacement of extracts by selected recombinant allergens is an emerging strategy for improving allergy diagnosis and immunotherapy. In this respect, recombinant production based on plant systems offers a number of advantages such as appropriate post-translational modifications and enhanced safety due to absence of animal or human pathogens. So far, several approaches to express allergens using plant systems have been published. Immunologically active Der p 2, a major house dust mite (HDM) allergen, has been expressed in BY-2 tobacco suspension cell cultures. Mal d 2, a thaumatin-like allergenic protein from apple, and Bet v 1, the major birch pollen allergen, both have been overexpressed in Nicotiana benthamiana using a tobacco mosaic virus (TMV) vector. The major mugwort pollen allergen Art v 1 has been expressed in both TMV and Agrobacterium-transformed tobacco plants. Other approaches have explored the possibility of using seeds of cereal crops as vehicles for production of recombinant allergens and as direct delivery system without the need of allergen extraction and purification. Prototypes of such edible vaccines have been produced for a major HDM allergen Der f 1 in Lotus japonicus, and for T cell epitopes of Japanese cedar pollen allergens in rice seeds.

M3 - Conference abstract in proceedings

SN - 978-951-38-6321-0

T3 - VTT Symposium

SP - 37

EP - 37

BT - Plants for Human Health in the Post-Genome Era

PB - VTT Technical Research Centre of Finland

CY - Espoo

ER -

Ferreira F, Schmidt G, Gadermaier G, Ritala A, Obermeyer G. Production of recombinant allergens in plants. In Plants for Human Health in the Post-Genome Era: PSE Congress. Espoo: VTT Technical Research Centre of Finland. 2007. p. 37-37. O22. (VTT Symposium; No. 249).